Oxford’daki ara\u015ft\u0131rmac\u0131lar, kanser\u00a0h\u00fccrelerinin ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden gizlenmesini \u00f6nlemek amac\u0131yla yeni bir ila\u00e7 geli\u015ftirdi. Bu ila\u00e7, ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin kanserli h\u00fccreleri tespit ederek yok etmesine olanak tan\u0131yor. \u0130ngiltere, Fransa, \u0130spanya\u00a0ve Avustralya’y\u0131 kapsayan denemelerde; rahim a\u011fz\u0131, mesane, karaci\u011fer, ba\u011f\u0131rsak, ak\u00e7i\u011fer\u00a0ile ba\u015f ve boyun kanseri olan 83 hastaya, “GRWD5769” adl\u0131 deneysel ila\u00e7la birlikte “cemiplimab” adl\u0131 imm\u00fcnoterapi ilac\u0131 verildi.
\u0130ngiltere’nin Manchester kentindeki Christie NHS Vakf\u0131 taraf\u0131ndan y\u00fcr\u00fct\u00fclen ara\u015ft\u0131rmada, 26 hastada t\u00fcm\u00f6rlerin k\u00fc\u00e7\u00fcld\u00fc\u011f\u00fc tespit edildi. Bu hastalar\u0131n 15’inde t\u00fcm\u00f6r boyutunda en az y\u00fczde 30 azalma kaydedildi.\u00c7al\u0131\u015fmaya kat\u0131lan hastalar\u0131n tamam\u0131n\u0131n daha \u00f6nce uygulanan tedavilere yan\u0131t vermedi\u011fi ve \u00e7o\u011funun ba\u015fka tedavi se\u00e7ene\u011finin kalmad\u0131\u011f\u0131 belirtildi. Hastalarda imm\u00fcnoterapi tedavisinin daha \u00f6nce hi\u00e7 i\u015fe yaramad\u0131\u011f\u0131 veya etkisini yitirdi\u011fi aktar\u0131ld\u0131.Geli\u015ftirilen ak\u0131ll\u0131 ila\u00e7, t\u00fcm\u00f6r h\u00fccrelerinin “g\u00f6r\u00fcnmezlik kalkan\u0131n\u0131” kald\u0131rarak onlar\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin enfeksiyon\u00a0ve hastal\u0131klarla sava\u015fan h\u00fccrelerine a\u00e7\u0131k hale getirdi. Bu sayede imm\u00fcnoterapi ilac\u0131, kanserli h\u00fccreleri hedef alarak yok edebildi.Ara\u015ft\u0131rman\u0131n sonu\u00e7lar\u0131, Chicago’da d\u00fczenlenen d\u00fcnyan\u0131n en b\u00fcy\u00fck kanser konferans\u0131 Amerikan Klinik Onkoloji Derne\u011fi (ASCO) y\u0131ll\u0131k toplant\u0131s\u0131nda sunuldu.GRWD5769 adl\u0131 ilac\u0131n, denemeye d\u00e2hil edilen alt\u0131 kanser t\u00fcr\u00fcn\u00fcn tamam\u0131nda t\u00fcm\u00f6rleri k\u00fc\u00e7\u00fcltt\u00fc\u011f\u00fc g\u00f6r\u00fcld\u00fc. \u0130la\u00e7, rahim a\u011fz\u0131 kanseri hastalar\u0131n\u0131n y\u00fczde 18’inde, karaci\u011fer kanseri hastalar\u0131n\u0131n y\u00fczde 32’sinde, mesane kanseri hastalar\u0131n\u0131n y\u00fczde 36’sinde, ba\u015f ve boyun kanseri hastalar\u0131n\u0131n y\u00fczde 38’inde, ba\u011f\u0131rsak\u00a0kanseri hastalar\u0131n\u0131n y\u00fczde 51’inde ve akci\u011fer kanseri hastalar\u0131n\u0131n y\u00fczde 55’inde hastal\u0131\u011f\u0131n ilerlemesini en az alt\u0131 ay boyunca durdurdu.<\/p>\n\n\n\n
Birinci evre klinik deneme sonu\u00e7lar\u0131n\u0131 konferansta sunan ara\u015ft\u0131rman\u0131n ba\u015f sorumlusu Prof. Fiona Thistlethwaite, hap \u015feklinde evde al\u0131nabilen bu ilac\u0131n erken a\u015famada g\u00f6sterdi\u011fi ba\u015far\u0131n\u0131n \u00e7ok etkileyici oldu\u011funu vurgulad\u0131. Thistlethwaite, yeni bir mekanizmayla \u00e7al\u0131\u015fan bu ilac\u0131n imm\u00fcnoterapinin daha etkili olmas\u0131na a\u00e7\u0131k\u00e7a katk\u0131 sa\u011flad\u0131\u011f\u0131n\u0131 ifade etti.<\/p>\n\n\n\n
Oxford merkezli Greywolf Therapeutics taraf\u0131ndan geli\u015ftirilen tabletlerin hastalar taraf\u0131ndan iyi tolere edildi\u011fi ve daha geni\u015f kapsaml\u0131 bir \u00e7al\u0131\u015fma i\u00e7in planlamalar\u0131n s\u00fcrd\u00fc\u011f\u00fc bildirildi.<\/p>\n\n\n\n
\u0130mm\u00fcnoterapi, ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin T h\u00fccrelerini kansere kar\u015f\u0131 sava\u015fmak \u00fczere devreye sokuyor. Ancak kanserli h\u00fccreler, “ERAP1” adl\u0131 bir enzimi manip\u00fcle ederek T h\u00fccrelerinden saklanabiliyor. Bu durum, imm\u00fcnoterapinin hastalar\u0131n yakla\u015f\u0131k \u00fc\u00e7te ikisinde ba\u015far\u0131s\u0131z olmas\u0131na yol a\u00e7\u0131yor.<\/p>\n\n\n\n
GRWD5769, ERAP1 enzimini bask\u0131layarak kanserin gizlenme mekanizmas\u0131n\u0131 ortadan kald\u0131r\u0131yor ve t\u00fcm\u00f6r h\u00fccrelerini yeniden g\u00f6r\u00fcn\u00fcr k\u0131l\u0131yor.<\/p>\n\n\n\n
Edinburgh Kanser Merkezi ve Edinburgh \u00dcniversitesi b\u00fcnyesinde \u00e7al\u0131\u015fmalar\u0131n\u0131 y\u00fcr\u00fcten Prof. Stefan Symeonides de sonu\u00e7lar\u0131 heyecan verici olarak nitelendirerek, bu yeni yakla\u015f\u0131m\u0131n klinik denemelere ta\u015f\u0131nmas\u0131ndan ve hastalar \u00fczerindeki olumlu etkilerinden memnuniyet duyduklar\u0131n\u0131 dile getirdi.<\/p>\n\n\n\n
\u0130ngiltere Kanser ara\u015ft\u0131rma Vakf\u0131ndan Dr. Samuel Godfrey ise daha \u00f6nce tedaviye yan\u0131t\u0131 durmu\u015f ve zorlu kanser t\u00fcrlerine sahip hastalarda bu a\u015famada b\u00f6yle sonu\u00e7lar al\u0131nmas\u0131n\u0131n umut verici oldu\u011funu, ancak yakla\u015f\u0131m\u0131n kal\u0131c\u0131 faydalar\u0131n\u0131 g\u00f6rmek i\u00e7in daha b\u00fcy\u00fck \u00e7apl\u0131 denemelere ihtiya\u00e7 duyuldu\u011funu belirtti.
Kaynak; TRT Haber 02.06.2026<\/p>\n","protected":false},"excerpt":{"rendered":"
Oxford’daki ara\u015ft\u0131rmac\u0131lar, kanser\u00a0h\u00fccrelerinin ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden gizlenmesini \u00f6nlemek amac\u0131yla yeni bir ila\u00e7 geli\u015ftirdi. Bu ila\u00e7, ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin kanserli h\u00fccreleri tespit ederek yok etmesine olanak tan\u0131yor. \u0130ngiltere, Fransa, \u0130spanya\u00a0ve Avustralya’y\u0131 kapsayan denemelerde;<\/p>\n","protected":false},"author":5,"featured_media":331,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[171],"tags":[173,135,176,172,178,177,174,175],"class_list":["post-329","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik","tag-akilli-ilac","tag-hastalik","tag-immunoterapi","tag-kanser","tag-kanser-arastirmasi","tag-kanser-tedavisi","tag-onkoloji","tag-saglik"],"_links":{"self":[{"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/posts\/329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/comments?post=329"}],"version-history":[{"count":4,"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/posts\/329\/revisions"}],"predecessor-version":[{"id":337,"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/posts\/329\/revisions\/337"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/media\/331"}],"wp:attachment":[{"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/media?parent=329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/categories?post=329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.beyazyorum.com\/index.php\/wp-json\/wp\/v2\/tags?post=329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}